<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933344</url>
  </required_header>
  <id_info>
    <org_study_id>397</org_study_id>
    <nct_id>NCT04933344</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections</brief_title>
  <acronym>PKTOXDAP</acronym>
  <official_title>Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of this study is to investigate the relationship between exposure to daptomycin and&#xD;
      the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with&#xD;
      daptomycin for bone and joint infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to&#xD;
      vancomycin, and recommended for this use by various learned societies including the&#xD;
      Infectious Diseases Society of America (IDSA) in 2013.&#xD;
&#xD;
      Tolerance to daptomycin is generally favorable, with in particular better renal tolerance&#xD;
      than vancomycin. However, two rare and potentially severe side effects have been described&#xD;
      with this antibiotics: muscle toxicity and eosinophilic pneumonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of patients having had a PJI or BJI treated by daptomycin</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>proportion of patients treated by daptomycin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>description of BJI/PJI</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>type of BJI or PJI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>description of patients</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>comorbidites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>description of adverse event</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>type of adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of patients having had an adverse event</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>proportion of patients having had an adverse event under daptomycin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evalutation of the adverse event due to daptomycin : dosage of daptomycine</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>description of the use of daptomycine : dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evalutation of the adverse event due to daptomycin : duration of daptomycine</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>description of the use of daptomycine : duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evalutation of the adverse event due to daptomycin : daptomycine plasma clearance</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>mean daptomycine plasma clearance (unit, liters per hour)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evalutation of the adverse event due to daptomycin : daptomycine volume distribution</measure>
    <time_frame>between 2010 and 2020</time_frame>
    <description>mean daptomycine volume of distribution (unit, liters)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1130</enrollment>
  <condition>Dactinomycin Adverse Reaction</condition>
  <condition>Bone and Joint Infection</condition>
  <arm_group>
    <arm_group_label>patients having had BJI or PJI treated with daptomycin</arm_group_label>
    <description>patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients having had BJI or PJI treated with daptomycin</intervention_name>
    <description>patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK</description>
    <arm_group_label>patients having had BJI or PJI treated with daptomycin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients managed at the CRIOAc Lyon who have had an osteoarticular infection, treated with&#xD;
        daptomycin, with at least one blood test for daptomycin performed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have had an osteoarticular infection, treated with daptomycin, with at&#xD;
             least one blood test for daptomycin performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who objected to participating in the study&#xD;
&#xD;
          -  Absence of blood dosage of daptomycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Tristan Ferry, Md,PhD</last_name>
    <phone>04 26 73 29 38</phone>
    <email>tristan.ferry@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugenie Mabrut, CRA</last_name>
    <phone>04 26 73 29 38</phone>
    <email>eugenie.mabrut@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenie Mabrut, CRA</last_name>
      <phone>04 26 73 29 38</phone>
      <email>eugenie.mabrut@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.crioac-lyon.fr/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone and joint infection</keyword>
  <keyword>adverse event</keyword>
  <keyword>daptomycin</keyword>
  <keyword>Eosinophilic pneumonia</keyword>
  <keyword>CPK</keyword>
  <keyword>rhabdomyolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

